Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial.

Hirte HW, Vidal L, Fleming GF, Sugimoto AK, Morgan RJ, Biagi JJ, Wang L, McGill S, Ivy SP, Oza AM. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or fallopian tube cancer: Final results of a PMH, Chicago and California consortia trial. J Clin Oncol. 2008 May 20; 26(15_suppl):5521.

View in: PubMed

collapse authors with profiles